PHT Corporation Speeds Clinical Trial Times with Vodaphone Global M2M Technology
Vodafone and PHT Corporation, the leading provider of technologies used to collect electronic data for clinical research from patients, are working together to connect the PHT electronic clinical outcome assessment (eCOA) system to Vodafone’s global M2M network. Using Vodafone’s global M2M network, PHT provides pharmaceutical trial sponsors real-time access to patient data enabling them to collect higher quality data and make faster research decisions with confidence. Currently the PHT eCOA System is used to collect data in hundreds of clinical trials in more than 75 countries.
Over the next three years, PHT will deliver thousands of tablets embedded with the Vodafone M2M SIM to clinical research sites across North and South America, Europe, Asia, and Africa. PHT will manage connections through the Vodafone Global M2M Platform to help ensure ease of use and satisfaction for patients and sites.
Clinical trial participants record information about their symptoms and experiences in the PHT SitePad® mobile tablet which stores all data collected privately and securely. The SitePad mobile tablet connects to StudyWorks, the PHT study management and patient data portal over the secure Vodafone global M2M network where all patient trial data will then be available for review, reporting and comparison.
“Clinical trials are conducted globally and ensuring every patient and clinical site can enter and send critical data regularly and reliably is challenging as connectivity is not uniform across the world,” said Sheila Rocchio, Vice President of Marketing and Corporate Strategy, PHT. “Partnering with Vodafone has given PHT greater flexibility and reliability in data connectivity across the globe helping to increase end user satisfaction with the PHT eCOA system.”
Vodafone’s Head of M2M for the Americas Andrew Morawski said, “Vodafone’s M2M technology is helping to transform lives. We’re delighted to work with PHT to enhance the effectiveness of clinical studies and make it easier to develop safe and innovative treatments for patients.”
PHT services 18 of the 20 largest pharmaceutical companies and more than 140 pharmaceutical companies in 75 countries.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
